Synexus Clinical Research Limited Sustainability Profile
Synexus Clinical Research Limited, a leading name in the clinical research industry, is headquartered in Great Britain and operates across multiple regions, including Europe and North America. Founded in 1997, Synexus has established itself as a pioneer in patient recruitment and clinical trial management, focusing on delivering high-quality research services to pharmaceutical and biotechnology companies. The company offers a unique blend of services, including site management, patient recruitment, and data management, which are tailored to meet the specific needs of each study. Synexus is renowned for its extensive patient database and innovative approaches, ensuring efficient trial execution and high patient retention rates. With a strong market position and a commitment to excellence, Synexus continues to achieve notable milestones in advancing clinical research and improving patient outcomes.
DitchCarbon Score
How does Synexus Clinical Research Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Synexus Clinical Research Limited's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Synexus Clinical Research Limited, headquartered in Great Britain, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Thermo Fisher Scientific Inc., which influences its climate commitments and initiatives. As part of its corporate family relationship, Synexus follows the sustainability and climate strategies set by Thermo Fisher Scientific Inc. This includes adherence to various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Thermo Fisher at a cascade level of 6. However, specific reduction targets or achievements for Synexus are not detailed in the available data. While no absolute emissions figures are provided, Synexus is committed to aligning with industry standards for climate action, reflecting a broader commitment to sustainability within the clinical research sector. The absence of specific emissions data highlights the need for ongoing transparency and accountability in their environmental impact reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Synexus Clinical Research Limited's Industry?
How Carbon Intensive is Synexus Clinical Research Limited's Location?
Synexus Clinical Research Limited's Scope 3 Categories Breakdown
Synexus Clinical Research Limited's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 37% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 58% of Scope 3 emissions.
Top Scope 3 Categories
Synexus Clinical Research Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Synexus Clinical Research Limited has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.